Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by Trexquant Investment LP

Trexquant Investment LP lifted its position in Illumina, Inc. (NASDAQ:ILMN) by 16.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 142,977 shares of the life sciences company’s stock after acquiring an additional 20,506 shares during the quarter. Trexquant Investment LP owned 0.09% of Illumina worth $19,106,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Golden State Wealth Management LLC bought a new position in Illumina during the fourth quarter worth $32,000. Versant Capital Management Inc lifted its position in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Illumina in the 4th quarter valued at about $45,000. Assetmark Inc. grew its position in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after buying an additional 296 shares during the last quarter. Finally, Lee Danner & Bass Inc. bought a new stake in shares of Illumina during the 4th quarter valued at about $48,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Down 0.8 %

Shares of Illumina stock opened at $79.34 on Tuesday. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12-month low of $77.54 and a 12-month high of $156.66. The firm has a market capitalization of $12.57 billion, a PE ratio of -10.33, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The stock’s fifty day moving average is $101.65 and its 200-day moving average is $126.49.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ILMN. Canaccord Genuity Group decreased their target price on Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a research note on Tuesday, March 11th. TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $177.00 to $140.00 in a research note on Friday, February 7th. Barclays reaffirmed an “underweight” rating on shares of Illumina in a research report on Tuesday, March 11th. HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target for the company. in a report on Friday, February 28th. Finally, Royal Bank of Canada dropped their price objective on shares of Illumina from $247.00 to $128.00 and set an “outperform” rating on the stock in a report on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Illumina currently has an average rating of “Moderate Buy” and a consensus target price of $140.90.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.